[
  {
    "ts": "2026-01-22T00:02:43+00:00",
    "headline": "J&J's Guidance Wallops Views, But Boston Scientific, Medtronic Take A Toll",
    "summary": "Johnson & Johnson stock dipped Wednesday despite a fourth-quarter beat as Medtronic and Boston Scientific continued gaining share in PFA.",
    "url": "https://www.investors.com/news/technology/johnson-and-johnson-stock-jnj-earnings-q4-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2a14968b-af49-395f-8455-489539a6620c",
      "content": {
        "id": "2a14968b-af49-395f-8455-489539a6620c",
        "contentType": "STORY",
        "title": "J&J's Guidance Wallops Views, But Boston Scientific, Medtronic Take A Toll",
        "description": "",
        "summary": "Johnson & Johnson stock dipped Wednesday despite a fourth-quarter beat as Medtronic and Boston Scientific continued gaining share in PFA.",
        "pubDate": "2026-01-22T00:02:43Z",
        "displayTime": "2026-01-22T00:02:43Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2a14968b-af49-395f-8455-489539a6620c/j-j-s-guidance-wallops-views-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/0ae2b2db37883f68ee2069be9bd594e4",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rwA2Kba4.xjpNvtEg7n9QQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/0ae2b2db37883f68ee2069be9bd594e4.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9I9e__rmE38egilIIeIqrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/0ae2b2db37883f68ee2069be9bd594e4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/johnson-and-johnson-stock-jnj-earnings-q4-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T02:50:00+00:00",
    "headline": "Is This Dividend King Stock a Buy After a Major Development?",
    "summary": "After a strong performance in 2025, Johnson & Johnson is starting the new year right.",
    "url": "https://www.fool.com/investing/2026/01/21/is-this-dividend-king-stock-a-buy-after-a-major-de/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1ce0c2ea-6a06-3795-8dc7-008936c4dd84",
      "content": {
        "id": "1ce0c2ea-6a06-3795-8dc7-008936c4dd84",
        "contentType": "STORY",
        "title": "Is This Dividend King Stock a Buy After a Major Development?",
        "description": "",
        "summary": "After a strong performance in 2025, Johnson & Johnson is starting the new year right.",
        "pubDate": "2026-01-22T02:50:00Z",
        "displayTime": "2026-01-22T02:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/09236348b2e17cadeda32e51081d92e5",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor and patient in a hospital room.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZVsnfs15n5_MVdj0fOur4g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/09236348b2e17cadeda32e51081d92e5.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8rzPV9pz9Clq_QNJVtYrFQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/09236348b2e17cadeda32e51081d92e5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/21/is-this-dividend-king-stock-a-buy-after-a-major-de/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dividend-king-stock-buy-major-025000516.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T07:05:00+00:00",
    "headline": "This 2.4%-Yielding Dividend King Remains As Healthy As Ever",
    "summary": "Johnson & Johnson had a strong year.",
    "url": "https://www.fool.com/investing/2026/01/22/this-24-yielding-dividend-king-remains-as-healthy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f279d2b1-0fa5-3639-9760-17f544ff5547",
      "content": {
        "id": "f279d2b1-0fa5-3639-9760-17f544ff5547",
        "contentType": "STORY",
        "title": "This 2.4%-Yielding Dividend King Remains As Healthy As Ever",
        "description": "",
        "summary": "Johnson & Johnson had a strong year.",
        "pubDate": "2026-01-22T07:05:00Z",
        "displayTime": "2026-01-22T07:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/32dbb966692a5ab590c3f628213c19d9",
          "originalWidth": 1400,
          "originalHeight": 931,
          "caption": "A person holding a syringe with Johnson & Johnson's logo in the background.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HFkao_DCpyDBM6pbo70amQ--~B/aD05MzE7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/32dbb966692a5ab590c3f628213c19d9.cf.webp",
              "width": 1400,
              "height": 931,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dJybwwGp4x47DnstB7Vubg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/32dbb966692a5ab590c3f628213c19d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/22/this-24-yielding-dividend-king-remains-as-healthy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-4-yielding-dividend-king-070500052.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T08:00:00+00:00",
    "headline": "Resolve M Therapeutics exits from stealth",
    "summary": "Resolve M Therapeutics, Inc., the biotech aiming to build the world's first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold com",
    "url": "https://finance.yahoo.com/news/resolve-m-therapeutics-exits-stealth-080000852.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b7a81820-0196-3596-b8ac-0ecf6fc88e09",
      "content": {
        "id": "b7a81820-0196-3596-b8ac-0ecf6fc88e09",
        "contentType": "STORY",
        "title": "Resolve M Therapeutics exits from stealth",
        "description": "",
        "summary": "Resolve M Therapeutics, Inc., the biotech aiming to build the world's first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold com",
        "pubDate": "2026-01-22T08:00:00Z",
        "displayTime": "2026-01-22T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f7b6e053f9f03ca9672cf1f457c51f9f",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JB1R9ihvmM7smb0WrilALw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/f7b6e053f9f03ca9672cf1f457c51f9f.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eV9bgxh73HO_MAN23D7_Bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7b6e053f9f03ca9672cf1f457c51f9f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/resolve-m-therapeutics-exits-stealth-080000852.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/resolve-m-therapeutics-exits-stealth-080000852.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T11:03:17+00:00",
    "headline": "Johnson & Johnson reports 9.1% increase in sales for Q4 2025",
    "summary": "For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share registered at $11.03.",
    "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-reports-sales-q4/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "08b161a0-dac4-359e-b6cb-53932cec85ac",
      "content": {
        "id": "08b161a0-dac4-359e-b6cb-53932cec85ac",
        "contentType": "STORY",
        "title": "Johnson & Johnson reports 9.1% increase in sales for Q4 2025",
        "description": "",
        "summary": "For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share registered at $11.03.",
        "pubDate": "2026-01-22T11:03:17Z",
        "displayTime": "2026-01-22T11:03:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/a2f139353ce4f7c65943f963f8cbd41d",
          "originalWidth": 1440,
          "originalHeight": 818,
          "caption": "J&J forecasts 2026 sales of $100.5bn and adjusted EPS of $11.53 at the midpoint. Credit: PixelBiss / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AItVwxsqnbf0SPmoqonQaA--~B/aD04MTg7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/a2f139353ce4f7c65943f963f8cbd41d.cf.webp",
              "width": 1440,
              "height": 818,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rYQwYqAATUI2cpF_nb9jgw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/a2f139353ce4f7c65943f963f8cbd41d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-reports-sales-q4/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-reports-9-1-110317238.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T05:01:00+00:00",
    "headline": "Housing Market’s Blue Christmas: Pending Sales Slide Most Since 2001",
    "summary": "The downturn comes at an interesting time: There are now 47% more sellers than buyers on the market, according to RedFin.",
    "url": "https://www.thedailyupside.com/economics/real-estate/pending-home-sales-plummet-in-december/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "83fb151e-c5b8-3db5-9158-dc3239fdace9",
      "content": {
        "id": "83fb151e-c5b8-3db5-9158-dc3239fdace9",
        "contentType": "STORY",
        "title": "Housing Market’s Blue Christmas: Pending Sales Slide Most Since 2001",
        "description": "",
        "summary": "The downturn comes at an interesting time: There are now 47% more sellers than buyers on the market, according to RedFin.",
        "pubDate": "2026-01-22T05:01:00Z",
        "displayTime": "2026-01-22T05:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/3df25ac61aced573656b2931703a71de",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Aerial photo of a neighborhood of US homes.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Iy_u3zuc50ZBxpqWjqZihQ--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/3df25ac61aced573656b2931703a71de.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nRvdEV81ksNdOzHb5tD4sA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/3df25ac61aced573656b2931703a71de.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/economics/real-estate/pending-home-sales-plummet-in-december/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/housing-market-blue-christmas-pending-050100341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T05:01:00+00:00",
    "headline": "Johnson & Johnson Crushes Patent, Pricing Probs",
    "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
    "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-overcomes-patent-and-pricing-probs/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "83ac5d47-79c6-3480-bb94-59e28df067fd",
      "content": {
        "id": "83ac5d47-79c6-3480-bb94-59e28df067fd",
        "contentType": "STORY",
        "title": "Johnson & Johnson Crushes Patent, Pricing Probs",
        "description": "",
        "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
        "pubDate": "2026-01-22T05:01:00Z",
        "displayTime": "2026-01-22T05:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/1e08a807ac8f7d9f274aa9b98d94e229",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of the Johnson & Johnson MedTech office building in Santa Clara, California.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nr86Y11pS4sCbCQI4._JxA--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/1e08a807ac8f7d9f274aa9b98d94e229.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vUVYM1W11zirRR8M_aQYGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/1e08a807ac8f7d9f274aa9b98d94e229.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-overcomes-patent-and-pricing-probs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-crushes-patent-pricing-050100914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T13:19:10+00:00",
    "headline": "Earnings live: GE Aerospace orders surge, Procter & Gamble and Abbott stocks dip",
    "summary": "A broader set of sectors will be represented when 35 more S&P 500 companies report earnings this week, including Netflix, Procter & Gamble, and Intel.",
    "url": "https://finance.yahoo.com/news/live/earnings-live-ge-aerospace-orders-surge-procter--gamble-and-abbott-stocks-dip-131910594.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "19cd1080-a43d-4393-8ed1-77d2b30d3322",
      "content": {
        "id": "19cd1080-a43d-4393-8ed1-77d2b30d3322",
        "contentType": "STORY",
        "title": "Earnings live: GE Aerospace orders surge, Procter & Gamble and Abbott stocks dip",
        "description": "",
        "summary": "A broader set of sectors will be represented when 35 more S&P 500 companies report earnings this week, including Netflix, Procter & Gamble, and Intel.",
        "pubDate": "2026-01-22T13:19:10Z",
        "displayTime": "2026-01-22T13:26:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/dd412560-f794-11f0-9bff-82d376762005",
          "originalWidth": 3679,
          "originalHeight": 2760,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lAHP6_q2GMzc9Es_HDpf5g--~B/aD0yNzYwO3c9MzY3OTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/dd412560-f794-11f0-9bff-82d376762005.cf.webp",
              "width": 3679,
              "height": 2760,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jVobDThtIu7ZaWOllHNUCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/dd412560-f794-11f0-9bff-82d376762005.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-ge-aerospace-orders-surge-procter--gamble-and-abbott-stocks-dip-131910594.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-ge-aerospace-orders-surge-procter--gamble-and-abbott-stocks-dip-131910594.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INTC"
            },
            {
              "symbol": "GE"
            },
            {
              "symbol": "FITB"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "COF"
            },
            {
              "symbol": "UAL"
            },
            {
              "symbol": "MMM"
            },
            {
              "symbol": "DHI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T14:59:45+00:00",
    "headline": "Jim Cramer on Johnson & Johnson: “One of the Best Pharmas There Is”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. During the episode, Cramer discussed the company’s earnings and the following market reaction, as he stated: Alright, what do we make of these earnings from Johnson & Johnson? This morning, the pharma titan reported a healthy revenue beat and a very modest […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-one-145945940.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a293b801-5b04-3fe3-8d89-8d7a706fbd3b",
      "content": {
        "id": "a293b801-5b04-3fe3-8d89-8d7a706fbd3b",
        "contentType": "STORY",
        "title": "Jim Cramer on Johnson & Johnson: “One of the Best Pharmas There Is”",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. During the episode, Cramer discussed the company’s earnings and the following market reaction, as he stated: Alright, what do we make of these earnings from Johnson & Johnson? This morning, the pharma titan reported a healthy revenue beat and a very modest […]",
        "pubDate": "2026-01-22T14:59:45Z",
        "displayTime": "2026-01-22T14:59:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/49de360447d6c3bc2d07313db7578ad2",
          "originalWidth": 1920,
          "originalHeight": 1275,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/juYYo0YaAiUa6UCsns0QCQ--~B/aD0xMjc1O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/49de360447d6c3bc2d07313db7578ad2.cf.webp",
              "width": 1920,
              "height": 1275,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iElAPtblrLfYGvSdm9myng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/49de360447d6c3bc2d07313db7578ad2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-one-145945940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-one-145945940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T14:04:30+00:00",
    "headline": "A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
    "summary": "A dual-income couple approaching retirement with $1.2 million in savings and Social Security benefits faces a critical question: Will this be enough? The answer depends heavily on coordinating Social Security claims and structuring portfolio withdrawals. The Financial Snapshot Portfolio: $1.2 million in retirement savings Income source: Social Security benefits from dual earners Key challenge: Coordinating ... A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
    "url": "https://247wallst.com/investing/2026/01/22/a-couples-1-2-million-portfolio-faces-a-3-9-withdrawal-rate-reality/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e4b11447-83b0-3802-98d5-a82bb9f2e4b0",
      "content": {
        "id": "e4b11447-83b0-3802-98d5-a82bb9f2e4b0",
        "contentType": "STORY",
        "title": "A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
        "description": "",
        "summary": "A dual-income couple approaching retirement with $1.2 million in savings and Social Security benefits faces a critical question: Will this be enough? The answer depends heavily on coordinating Social Security claims and structuring portfolio withdrawals. The Financial Snapshot Portfolio: $1.2 million in retirement savings Income source: Social Security benefits from dual earners Key challenge: Coordinating ... A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
        "pubDate": "2026-01-22T14:04:30Z",
        "displayTime": "2026-01-22T14:04:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/bedaef5245eb247a73f70fa7186b854f",
          "originalWidth": 1500,
          "originalHeight": 1000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7NW8ix4ww6oEJyn2zRHsoA--~B/aD0xMDAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/bedaef5245eb247a73f70fa7186b854f.cf.webp",
              "width": 1500,
              "height": 1000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IzbSQqpzPP07TTZgNGQ7xQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/bedaef5245eb247a73f70fa7186b854f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/22/a-couples-1-2-million-portfolio-faces-a-3-9-withdrawal-rate-reality/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/couple-1-2-million-portfolio-140430765.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BND"
            },
            {
              "symbol": "VBMFX"
            },
            {
              "symbol": "VBMPX"
            },
            {
              "symbol": "VBTIX"
            },
            {
              "symbol": "VBTLX"
            },
            {
              "symbol": "VTBSX"
            },
            {
              "symbol": "VHYAX"
            },
            {
              "symbol": "VYM"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "MORN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T14:00:04+00:00",
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004049.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b579e93e-7859-3240-a659-be58d8be6ce6",
      "content": {
        "id": "b579e93e-7859-3240-a659-be58d8be6ce6",
        "contentType": "STORY",
        "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
        "description": "",
        "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
        "pubDate": "2026-01-22T14:00:04Z",
        "displayTime": "2026-01-22T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T15:08:05+00:00",
    "headline": "Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
    "summary": "A 70-year-old investor with $2.5 million in blue-chip dividend stocks faces a question many retirees wrestle with: is playing it safe actually risky? On Reddit’s r/Bogleheads forum, one user questioned whether their early-70s father’s portfolio with just 10% in stocks was too conservative, noting it “seems just almost too conservative, where it’s almost at a ... Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
    "url": "https://247wallst.com/investing/2026/01/22/playing-it-safe-at-70-with-2-5-million-is-likely-to-backfire/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "fb83b38c-46c8-3b4b-9af6-cf9ceb35c628",
      "content": {
        "id": "fb83b38c-46c8-3b4b-9af6-cf9ceb35c628",
        "contentType": "STORY",
        "title": "Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
        "description": "",
        "summary": "A 70-year-old investor with $2.5 million in blue-chip dividend stocks faces a question many retirees wrestle with: is playing it safe actually risky? On Reddit’s r/Bogleheads forum, one user questioned whether their early-70s father’s portfolio with just 10% in stocks was too conservative, noting it “seems just almost too conservative, where it’s almost at a ... Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
        "pubDate": "2026-01-22T15:08:05Z",
        "displayTime": "2026-01-22T15:08:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/e759685dd083c2fd444c3a3a96585668",
          "originalWidth": 1376,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cdKKW_o6ZGfnml_HlYB8.g--~B/aD03Njg7dz0xMzc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/e759685dd083c2fd444c3a3a96585668.cf.webp",
              "width": 1376,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jQxD0BJLwnbW.k1WsQ5RbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/e759685dd083c2fd444c3a3a96585668.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/22/playing-it-safe-at-70-with-2-5-million-is-likely-to-backfire/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/playing-safe-70-2-5-150805690.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VZ"
            },
            {
              "symbol": "BTAL"
            },
            {
              "symbol": "AGG"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T14:15:00+00:00",
    "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
    "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
    "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f5fef165-ab14-3534-b7b8-9cc6de40c73d",
      "content": {
        "id": "f5fef165-ab14-3534-b7b8-9cc6de40c73d",
        "contentType": "STORY",
        "title": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
        "description": "",
        "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
        "pubDate": "2026-01-22T14:15:00Z",
        "displayTime": "2026-01-22T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T16:19:00+00:00",
    "headline": "Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.",
    "summary": "Shares of  Abbott Laboratories  tumbled on Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street.  For the fourth quarter,  Abbott  reported adjusted earnings of $1.50 a share, slightly better than the $1.49 consensus among analysts tracked by  FactSet  The company logged roughly $11.5 billion in sales, missing the $11.8 billion analysts had forecast.  The company said it expects full-year adjusted earnings in the range of $5.55 to $5.80 a share.",
    "url": "https://www.barrons.com/articles/abbott-labs-earnings-stock-price-b161c508?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d8d96c38-e1f1-3d36-a0d9-e7abf134a676",
      "content": {
        "id": "d8d96c38-e1f1-3d36-a0d9-e7abf134a676",
        "contentType": "STORY",
        "title": "Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.",
        "description": "",
        "summary": "Shares of  Abbott Laboratories  tumbled on Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street.  For the fourth quarter,  Abbott  reported adjusted earnings of $1.50 a share, slightly better than the $1.49 consensus among analysts tracked by  FactSet  The company logged roughly $11.5 billion in sales, missing the $11.8 billion analysts had forecast.  The company said it expects full-year adjusted earnings in the range of $5.55 to $5.80 a share.",
        "pubDate": "2026-01-22T16:19:00Z",
        "displayTime": "2026-01-22T16:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d8d96c38-e1f1-3d36-a0d9-e7abf134a676/abbott-stock-slumps-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/6745c21cb507c1ad6c0b758f8bdfc5e2",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qqfRWPpOqNrb_ZubzxoOdA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/6745c21cb507c1ad6c0b758f8bdfc5e2.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZAU_YFUhN7t2YFAhGBs6kA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/6745c21cb507c1ad6c0b758f8bdfc5e2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbott-labs-earnings-stock-price-b161c508?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T11:36:00+00:00",
    "headline": "FDA lays out new path to speed development of multiple myeloma drugs",
    "summary": "In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.",
    "url": "https://www.biopharmadive.com/news/fda-multiple-myeloma-accelerated-approval-pathway/810219/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "cab78873-ab5b-31c8-aea2-7b2a52990765",
      "content": {
        "id": "cab78873-ab5b-31c8-aea2-7b2a52990765",
        "contentType": "STORY",
        "title": "FDA lays out new path to speed development of multiple myeloma drugs",
        "description": "",
        "summary": "In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.",
        "pubDate": "2026-01-22T11:36:00Z",
        "displayTime": "2026-01-22T11:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/16e1be3cb3e6e1a5ad1808f1977ec872",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "The U.S. Food and Drug Administration headquarters in Silver Spring, Md., on Nov. 10, 2020.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZI.KPTB2Uxomkd8lIiMpBQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/16e1be3cb3e6e1a5ad1808f1977ec872.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VzogcFtDEcM9TG2OzXvqCA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/16e1be3cb3e6e1a5ad1808f1977ec872.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/fda-multiple-myeloma-accelerated-approval-pathway/810219/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-lays-path-speed-development-113600335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T17:03:00+00:00",
    "headline": "ABBV vs. MRK: An Oncology-Immunology Showdown for Investors",
    "summary": "ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.",
    "url": "https://finance.yahoo.com/news/abbv-vs-mrk-oncology-immunology-170300512.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c6eda5a7-efd4-3ad5-aa13-44532a804dd0",
      "content": {
        "id": "c6eda5a7-efd4-3ad5-aa13-44532a804dd0",
        "contentType": "STORY",
        "title": "ABBV vs. MRK: An Oncology-Immunology Showdown for Investors",
        "description": "",
        "summary": "ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.",
        "pubDate": "2026-01-22T17:03:00Z",
        "displayTime": "2026-01-22T17:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bdd0e.RoBSjHIn04n3M0yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XexxwPCdNfrBiKnJILL27g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbv-vs-mrk-oncology-immunology-170300512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbv-vs-mrk-oncology-immunology-170300512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T16:45:02+00:00",
    "headline": "Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-top-164502169.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "da297c74-d67d-34d8-bd80-bb5c470fa864",
      "content": {
        "id": "da297c74-d67d-34d8-bd80-bb5c470fa864",
        "contentType": "STORY",
        "title": "Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio",
        "description": "",
        "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
        "pubDate": "2026-01-22T16:45:02Z",
        "displayTime": "2026-01-22T16:45:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
          "originalWidth": 1000,
          "originalHeight": 603,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YgRrCYuBdR1wa08RtjoPHQ--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9.cf.webp",
              "width": 1000,
              "height": 603,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jAWLk_UfDMDSToA2irhEEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-top-164502169.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-top-164502169.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]